Fused Heterocyclic Kinase Modulators for Btk Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kinase inhibitors, particularly for Bruton's tyrosine kinase (Btk), face challenges in stability, bioavailability, and therapeutic index, limiting their effectiveness in treating autoimmune and inflammatory diseases.
Innovation Solution
Development of substituted fused heterocyclic compounds, specifically imidazotriazines and imidazopyrazines, which act as potent kinase modulators, including Btk inhibitors, with improved stability, bioavailability, and therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current kinase inhibitors are used to treat autoimmune and inflammatory diseases, then Btk activity is inhibited, but stability and bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of kinase inhibitors through specific fused heterocyclic core structures (imidazotriazine, imidazopyrazine) and substituent patterns. These structural parameter changes result in compounds with improved metabolic stability and bioavailability while maintaining Btk inhibitory activity, directly resolving the contradiction between therapeutic effectiveness and compound stability
Solution Approach 2:
The patent employs composite material principles by creating complex fused heterocyclic compounds that combine multiple heterocyclic rings with various substituent groups. This composite molecular structure approach enhances the overall stability and bioavailability profile of the inhibitors while preserving their kinase modulating activity, addressing the limitations of simpler inhibitor structures
2Reliability
If current kinase inhibitors are used to treat autoimmune and inflammatory diseases, then Btk activity is inhibited, but bioavailability is limited
Solution Approach 1:
The patent utilizes parameter changes by optimizing molecular weight, lipophilicity, and hydrogen bonding capacity through careful selection of substituents on the fused heterocyclic core. These parameter optimizations improve oral bioavailability and tissue penetration while maintaining potent Btk inhibition, directly addressing the bioavailability limitation of current inhibitors
Solution Approach 2:
The patent applies equipotentiality principles by designing compounds with balanced physicochemical properties that achieve optimal absorption, distribution, metabolism, and excretion (ADME) characteristics. The fused heterocyclic structures are engineered to have appropriate lipophilicity and solubility profiles, creating a balance that maximizes bioavailability across different physiological conditions
3Reliability
If current kinase inhibitors are used to treat autoimmune and inflammatory diseases, then Btk activity is inhibited, but therapeutic index is insufficient
Solution Approach 1:
The patent applies local quality principles by introducing specific functional groups and substituents at particular positions on the fused heterocyclic core structure. These localized modifications enhance selectivity for Btk over other kinases, improving the therapeutic index by reducing off-target effects while maintaining potent inhibition of the intended target
Solution Approach 2:
The patent utilizes parameter changes by optimizing the binding affinity and selectivity through systematic variation of substituent types and positions. These changes improve the ratio of target to off-target inhibition, thereby enhancing the therapeutic index and reducing harmful side effects associated with non-selective kinase inhibition
Data Source
AI summary
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation, wherein R1, R2, R3, R4, Q, A and B are as defined herein.